Neurogene (NGNE) Accounts Payables (2013 - 2026)

Neurogene's Accounts Payables history runs 11 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• Quarterly Accounts Payables rose 52.95% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 52.95% YoY) and the FY2025 annual result came in at $2.0 million, up 46.18% from the prior year.
• Accounts Payables was $4.7 million for Q1 2026 at Neurogene, up from $2.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.9 million in Q3 2022 and bottomed at $625000.0 in Q4 2022.
• A 5-year average of $3.4 million and a median of $2.6 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 91.57% — and 2023, when it surged 315.36%.
• Neurogene's Accounts Payables stood at $625000.0 in 2022, then jumped by 315.36% to $2.6 million in 2023, then slumped by 48.54% to $1.3 million in 2024, then jumped by 46.18% to $2.0 million in 2025, then surged by 139.89% to $4.7 million in 2026.
• Business Quant data shows NGNE's Accounts Payables at $4.7 million in Q1 2026, $2.0 million in Q4 2025, and $1.5 million in Q3 2025.